Navigation Links
New pan-European collaboration launched into the diagnosis and control of coeliac disease
Date:4/9/2008

12 million, equivalent to nearly 9.5 million has been invested by the European Commission into a new pan-European partnership which will design an advanced diagnostic tool for the detection and control of coeliac disease, the most under-diagnosed common chronic condition in the UK today.

The collaborative project, entitled Coeliac Disease Management Monitoring Diagnosis using Biosensors and Integrated Chip Systems (CD-MEDICS), will unite technologies to allow point of care diagnostics, combined with embedded communication technologies to directly interface with hospital information systems. It is expected that the development of the technologies involved and their combination in a single product represent a significant advance in diagnostic technology that has the potential to be applied to the detection of a range of other conditions such, insulin dependent diabetes mellitus or rheumatoid arthritis.

At least 1 in 1001 people in the UK is estimated to suffer from coeliac disease a potentially life-threatening auto-immune condition caused by intolerance to gluten. However, according to a recent study2, only 12.5% of people with the disease are actually being correctly diagnosed. Recent research showed that the average length of time taken for someone to be diagnosed with coeliac disease from the onset of their symptoms is 13 years.

Coeliac disease is not a food allergy but a life-long autoimmune disease caused by intolerance to gluten, a protein found in wheat, barley and rye. For people with coeliac disease, eating gluten damages the lining of the gut, which prevents normal digestion and the absorption of food. There are serious health problems associated with coeliac disease including osteoporosis, gastro-intestinal cancer and increased risk of other autoimmune diseases. The only treatment is a strict gluten-free diet for life. The new diagnostic tool aims to help with early detection and to monitor adherence to the diet.

The project aims to develop a point of care screening device to be implemented at the primary care level. The proposed disposable microchip used to screen for coeliac disease will be used in a portable hand-held device, which will have embedded communication abilities allowing direct storage of test results on a patients electronic medical record. This will enable easy follow-up, management and monitoring of the patients response to withdrawal of gluten from the diet.

The screening device is capable of carrying out multi-analyte tests with the simultaneous detection of coeliac disease associated auto-antibodies (IgA and IgG gliadin, glutenin and tissue transglutaminase) and HLA-DQ2 and DQ8 genes. The analysis of the HLA-DQ2 and DQ8 will give information as to the genetic predisposition of an individual to developing coeliac disease, and the detection of the antibodies will allow for the early diagnosis of coeliac disease (and its recurrence if the gluten-free diet is not complied with).

The pan-European collaboration includes a number of UK-based organisations. Coeliac UK, the charity for people with coeliac disease and Dermatitis Herpetiformis (DH), is leading on training of healthcare professionals about the disease and new technology. Newcastle University is responsible for the development and delivery of the development of a sensing technology platform in the screening device. Researchers at Kings College London will be leading on the development of an anti-glutenin antibody test and the CD MEDICS project is being managed by a company specialising in research project management, iXscient Ltd.


'/>"/>

Contact: Kate Newman
kate.newman@coeliac.org.uk
020-839-97478
Coeliac UK
Source:Eurekalert

Related medicine news :

1. Paving the way for future pan-European clinical trials
2. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
3. American Red Cross and FedEx Announce Collaboration to Help Small Businesses Get Prepared for Disaster
4. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
5. NIH selects Weill Cornell Medical College to lead new NYC translational research collaboration
6. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
7. London School of Hygiene to play key role in global collaboration on adverse drug reactions
8. Chemizon Announces Research Collaboration Expansion With Takeda
9. Isis Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil, Inc.
10. American Diabetes Association Announces Three Year Collaboration With The Dignity Memorial(R) Network
11. Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
Breaking Medicine Technology: